Jazz Pharmaceuticals (JAZZ) EBT (2016 - 2025)
Historic EBT for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $9.0 million.
- Jazz Pharmaceuticals' EBT fell 9550.07% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$392.5 million, marking a year-over-year decrease of 19845.36%. This contributed to the annual value of $470.4 million for FY2024, which is 5787.35% up from last year.
- Jazz Pharmaceuticals' EBT amounted to $9.0 million in Q3 2025, which was down 9550.07% from -$735.6 million recorded in Q2 2025.
- In the past 5 years, Jazz Pharmaceuticals' EBT registered a high of $200.8 million during Q3 2024, and its lowest value of -$735.6 million during Q2 2025.
- Moreover, its 5-year median value for EBT was $15.0 million (2022), whereas its average is -$24.7 million.
- As far as peak fluctuations go, Jazz Pharmaceuticals' EBT crashed by 65840.51% in 2022, and later soared by 77116.21% in 2023.
- Quarter analysis of 5 years shows Jazz Pharmaceuticals' EBT stood at -$44.8 million in 2021, then tumbled by 658.41% to -$340.0 million in 2022, then skyrocketed by 118.1% to $61.5 million in 2023, then soared by 116.52% to $133.2 million in 2024, then plummeted by 93.22% to $9.0 million in 2025.
- Its EBT was $9.0 million in Q3 2025, compared to -$735.6 million in Q2 2025 and $133.2 million in Q4 2024.